کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5656731 1407375 2016 4 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Ézétimibe : plus de preuves pour un effet sur la réduction du risque cardiovasculaire
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی غدد درون ریز، دیابت و متابولیسم
پیش نمایش صفحه اول مقاله
Ézétimibe : plus de preuves pour un effet sur la réduction du risque cardiovasculaire
چکیده انگلیسی
Ezetimibe is an agent reducing intestinal cholesterol absorption by inhibiting NPC1L1 transporter. This reduction in cholesterol absorption induces, via a decrease in the cholesterol pool in the hepatocytes, an increase in LDL receptor expression leading to enhance LDL-cholesterol (LDLc) catabolism and, as a consequence, to reduce plasma LDLc level. Recently, came out important pieces of evidence for the efficiency of ezetimibe to reduce cardiovascular risk. A large Genome Wide Association Study showed that individuals with inactivating mutations of NPC1L1 had, in parallel with a decreased LDLc plasma level, a significant reduced cardiovascular risk. The PRECISE-IVUS study demonstrated a higher rate of coronary atherosclerotic plaque regression in patients treated with atorvastatin + ezetimibe compared to those treated with atorvastatin alone. In addition, the prospective IMPROVE-IT trial, had shown a significant reduction in major cardiovascular events (P=0.016), in myocardial infarction (P=0.002), in ischemic stroke (P=0.008), in coronary mortality (P=0.02), and in cardiovascular mortality (P=0.04) in patients treated with simvastatin + ezetimibe compared to those treated with simvastatin alone.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Médecine des Maladies Métaboliques - Volume 10, Issue 5, September 2016, Pages 430-433
نویسندگان
,